康复新液联合沙利度胺防治鼻咽癌患者放射性口腔黏膜炎的临床效果  

Clinical Effect of Kangfuxin Liquid Combined with Sunitinib in the Management of Radioactive Oral Mucositis in NPC Patients

作　　者：龚丹[1] 刘艳 付舒敏 姚兆鹏[2] GONG Dan;LIU Yan;FU Shu-min;YAO Zhao-peng(Department of Oncology,the Second Affiliated Hospital of Nanchang University;Department of orthopedics,Nanchang City First Hospital,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院肿瘤科 [2]南昌市第一医院骨科,南昌330006

出　　处：《实用临床医学（江西）》2024年第3期10-13,29,共5页Practical Clinical Medicine

基　　金：江西省中医药管理局科技计划(2020A0153)。

摘　　要：目的 探究康复新液联合沙利度胺预防鼻咽癌(NPC)患者放射性口腔黏膜炎(ROM)的临床效果。方法选取2021—2022年就诊于南昌大学第二附属医院的NPC患者60例,采用随机数字表法分为试验组和对照组,各30例。对照组自放疗开始,每日使用复方漱口液含漱和沙利度胺片口服,试验组在对照组基础上加用康复新液,2组均治疗至放疗结束。比较2组ROM发生情况、放射口腔受量、客观缓解率及不良反应的发生情况。结果 第4、6、8周时,试验组ROM的发生率显著低于对照组(P<0.05),且整个放疗期间试验组3、4级ROM的发生率也低于对照组(P<0.05)。2组口腔照射剂量体积的平均剂量、V30、V40、V50、V55、客观缓解率及不良反应发生率比较,差异均无统计学意义(P>0.05)。结论 康复新液联合沙利度胺可降低NPC患者ROM的发生率并减轻其严重程度。Objective To investigate the clinical effect of Kangfuxin liquid combined with sunitinib in preventing radioactive oral mucositis(ROM)in patients with nasopharyngeal carcinoma(NPC).Methods 60 NPC patients admitted to the Second Affiliated Hospital of Nanchang University from 2021 to 2022 were selected for the study and randomly divided into the experimental group and the control group,each with 30 cases.The control group was treated with daily gargling with compound mouthwash and oral administration of sunitinib tablets since the beginning of radiotherapy,whereas the experimental group was further treated with Kangfuxin liquid;the above treatments lasted until the end of radiotherapy in both groups.The occurrence of ROM,radiation oral tolerance,objective remission rate and the occurrence of adverse reactions were compared between the 2 groups.Results At weeks 4,6,and 8,the incidence of ROM in the experimental group was significantly lower than that in the control group(P<0.05),and the incidence of grade 3 and 4 ROM in the experimental group was also lower than that in the control group during the whole radiotherapy period(P<0.05).Comparisons of the mean dose of oral irradiation dose volume,V30,V40,V50,V55,the rate of objective remission,and the incidence of adverse reactions showed no statistically significant differences between the 2 groups(P>0.05).ConclusionThe findings suggest that Kangfuxin liquid combined with sunitinib can reduce the incidence and severity of ROM in NPC patients.

关 键 词：康复新液 沙利度胺 放射性口腔黏膜炎 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]